Abstract: Compounds that are selective inhibitors of Smad3 activation are disclosed. The compounds have the following structure: in which Z is an oxadiazole. The compounds disclosed are useful in treatment of fibrotic disease, particularly renal fibrosis, and similar diseases associated with the dysregulation of the HIPK2/Smad3 signaling pathway.

Abstract: Compounds that are selective inhibitors of Smad3 activation are disclosed. The compounds have the following structure: in which Z is an oxadiazole. The compounds disclosed are useful in treatment of fibrotic disease, particularly renal fibrosis, and similar diseases associated with the dysregulation of the HIPK2/Smad3 signaling pathway.

Abstract: Provided are a distillate oil hydrogenation deacidification catalyst containing a molecular sieve, preparation and use thereof. In this catalyst, the weight of the catalyst, on the basis of 100%, is 1-5% magnesium calculated as an oxide, 1-20% alumino-phosphate molecular sieve and/or aluminosilicate molecular sieve; 1-10% Co and/or Ni; 5-30% Mo and/or W, and the balance is aluminium oxide. The catalyst is prepared through forming, dipping and baking. The catalyst is very active in hydrogenation deacidification, and also in hydrodesulfurization and hydrodenitrogenation.